Live Breaking News & Updates on Ultragenyx Pharmaceutical Company Profile|Page 8

Stay updated with breaking news from Ultragenyx pharmaceutical company profile. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Issues Quarterly Earnings Results, Misses Expectations By $0.36 EPS

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($2.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.97) by ($0.36), Briefing.com reports. The business had revenue of $100.50 million for the quarter, compared to the consensus estimate of $103.90 million. Ultragenyx Pharmaceutical […] ....

New Zealand General , New Zealand , Theodore Alan Huizenga , Emild Kakkis , Robertw Baird , Camillel Bedrosian , Blackrock Inc , Vanguard Group Inc , Wellington Management Group , Ultragenyx Pharmaceutical Inc , Clearbridge Investments , Credit Suisse Group , Cantor Fitzgerald , Morgan Stanley , Canaccord Genuity Group , Ultragenyx Pharmaceutical Company Profile , Ultragenyx Pharmaceutical , Get Rating , Alan Huizenga , Management Group , State Street Corp , Street Corp , Suisse Group , Genuity Group , Ultragenyx Pharmaceutical Daily , Nasdaq Rare ,

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Sells $197,010.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) EVP Karah Herdman Parschauer sold 4,378 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, May 4th. The stock was sold at an average price of $45.00, for a total value of $197,010.00. Following the transaction, the executive vice president now directly owns 51,982 shares in the […] ....

New Zealand General , New Zealand , Emild Kakkis , Robertw Baird , Karah Herdman Parschauer , Cantor Fitzgerald , Ultragenyx Pharmaceutical Inc , Morgan Stanley , Ultragenyx Pharmaceutical Company Profile , Credit Suisse Group , Norges Bank , Canaccord Genuity Group , Wellington Management Group , Ultragenyx Pharmaceutical , Get Rating , Herdman Parschauer , Genuity Group , Suisse Group , Partners Management , Street Corp , Management Group , Ultragenyx Pharmaceutical Daily , Nasdaq Rare , Insider Trading , Nsider Trades ,

Ultragenyx Pharmaceutical (NASDAQ:RARE) Coverage Initiated at Cantor Fitzgerald

Analysts at Cantor Fitzgerald started coverage on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) in a research report issued to clients and investors on Wednesday, The Fly reports. The brokerage set an “overweight” rating and a $114.00 price target on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price target would indicate a potential upside of […] ....

Cantor Fitzgerald , Theodore Alan Huizenga , Camillel Bedrosian , Robertw Baird , Emild Kakkis , Ultragenyx Pharmaceutical Company Profile , Credit Suisse Group , China Universal Asset Management Co , Ultragenyx Pharmaceutical Inc , Lazard Asset Management , High Net Worth Advisory Group , Securities Exchange Commission , Quadrant Capital Group , Ultragenyx Pharmaceutical , Get Rating , Suisse Group , Alan Huizenga , Exchange Commission , Universal Asset Management , Asset Management , Capital Group , Net Worth Advisory Group , Ultragenyx Pharmaceutical Daily , Nasdaq Rare , Initiated Coverage ,

Ultragenyx Pharmaceutical (RARE) Set to Announce Earnings on Thursday

Should You Buy or Sell Ultragenyx Pharmaceutical Stock? Get The Latest RARE Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat. ....

Emild Kakkis , Robertw Baird , Theodore Alan Huizenga , Camillel Bedrosian , Us Bancorp , Lazard Asset Management , Advisor Group Holdings Inc , Ultragenyx Pharmaceutical Company Profile , Chartwell Investment Partners , Securities Exchange Commission , Cantor Fitzgerald , Canaccord Genuity Group , Credit Suisse Group , Fund Management Co , Ultragenyx Pharmaceutical Inc , Ultragenyx Pharmaceutical , Get Rating , Suisse Group , Genuity Group , Exchange Commission , Alan Huizenga , Asset Management , Investment Partners , Fund Management , Group Holdings , Ultragenyx Pharmaceutical Daily ,

Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Insider Sells $17,757.85 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) insider Dennis Karl Huang sold 389 shares of the stock in a transaction dated Wednesday, March 1st. The shares were sold at an average price of $45.65, for a total value of $17,757.85. Following the completion of the sale, the insider now directly owns 75,314 shares in the […] ....

Dennis Karl Huang , Robertw Baird , Morgan Stanley , Ultragenyx Pharmaceutical Inc , High Net Worth Advisory Group , Credit Suisse Group , Ultragenyx Pharmaceutical Company Profile , Quadrant Capital Group , Lazard Asset Management , China Universal Asset Management Co , Ultragenyx Pharmaceutical , Get Rating , Universal Asset Management , Asset Management , Capital Group , Net Worth Advisory Group , Suisse Group , Ultragenyx Pharmaceutical Daily , Nasdaq Rare , Insider Trading , Nsider Trades ,